KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) FCF Margin (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed FCF Margin for 15 consecutive years, with 9.19% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin fell 1619.0% to 9.19% in Q4 2025 year-over-year; TTM through Dec 2025 was 6.4%, a 1947.0% decrease, with the full-year FY2025 number at 6.4%, down 1947.0% from a year prior.
  • FCF Margin was 9.19% for Q4 2025 at Supernus Pharmaceuticals, up from 32.17% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 41.8% in Q2 2022 to a low of 32.17% in Q3 2025.
  • A 5-year average of 18.05% and a median of 24.3% in 2023 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: soared 3517bps in 2024, then crashed -6252bps in 2025.
  • Supernus Pharmaceuticals' FCF Margin stood at 30.66% in 2021, then tumbled by -46bps to 16.48% in 2022, then skyrocketed by 66bps to 27.38% in 2023, then fell by -7bps to 25.38% in 2024, then plummeted by -64bps to 9.19% in 2025.
  • Per Business Quant, the three most recent readings for SUPN's FCF Margin are 9.19% (Q4 2025), 32.17% (Q3 2025), and 35.1% (Q2 2025).